They are receiving new doses to stop the virus that causes bronchiolitis after vaccinating almost 4,000 children in Castellón.

The plenary meeting of the Council approved a two-year contract worth 15.2 million euros for the supply of 70 thousand doses of the monoclonal antibody Niirsemivab against respiratory synthymic virus (VRS) intended for the childhood vaccination program.

During the latest campaign, 3,934 minors in the province of Castellon were vaccinated against RSV, which causes the vast majority of infections. bronchiolitis in infants and for conditions such as persistent wheezing or pneumonia.

The goal is to acquire the necessary doses of the prophylactic agent, which allowed reduce hospitalizations by 80%. The defender’s target groups are all children under 6 months of age and children under 2 years of age who belong to a risk group. In particular, in Castellón, during the last campaign, 3,698 children under one year of age, born between April 1 and March 31, 2024 (this is where immunization is established), as well as 102 premature children under 35 weeks of age, were vaccinated. 26 children with congenital heart disease. diseases and another 108 who had various pathologies are also included in the protocol.

In the Community, the vaccination strategy against RSV began to be implemented from 1 October 2023 to 31 March 2024, taking into account the circulation of the virus. During this period, more than 34,000 children in the Community were vaccinated.